Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Humana Inc’s stock clocked out at $258.32, up 0.17% from its previous closing price of $257.87. In other words, the price has increased by $0.17 from its previous closing price. On the day, 1.61 million shares were traded. HUM stock price reached its highest trading level at $262.63 during the session, while it also had its lowest trading level at $256.285.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 22, 2025, initiated with a In-line rating and assigned the stock a target price of $295.
On May 01, 2025, Raymond James Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $315. BofA Securities Upgraded its Underperform to Neutral on November 06, 2024, whereas the target price for the stock was revised from $247 to $308.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 14 ’25 when Rechtin James A. bought 6,530 shares for $229.25 per share. The transaction valued at 1,496,984 led to the insider holds 30,474 shares of the business.
Diamond Susan M bought 10,959 shares of HUM for $2,732,134 on Apr 08 ’25. On Feb 24 ’25, another insider, Huval Timothy S., who serves as the Former Chief Administrative Of of the company, bought 1,247 shares for $258.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUM now has a Market Capitalization of 31068616704 and an Enterprise Value of 22342617088. As of this moment, Humana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.83, and their Forward P/E ratio for the next fiscal year is 18.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.25 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 0.181 whereas that against EBITDA is 5.565.
Stock Price History:
The Beta on a monthly basis for HUM is 0.42, which has changed by -0.17191857 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, HUM has reached a high of $324.38, while it has fallen to a 52-week low of $206.87. The 50-Day Moving Average of the stock is -3.65%, while the 200-Day Moving Average is calculated to be -1.08%.
Shares Statistics:
It appears that HUM traded 1.78M shares on average per day over the past three months and 2277050 shares per day over the past ten days. A total of 120.27M shares are outstanding, with a floating share count of 119.99M. Insiders hold about 0.23% of the company’s shares, while institutions hold 95.40% stake in the company. Shares short for HUM as of 1756425600 were 4625645 with a Short Ratio of 2.60, compared to 1753920000 on 4682779. Therefore, it implies a Short% of Shares Outstanding of 4625645 and a Short% of Float of 4.32.
Dividends & Splits
With its trailing 12-month dividend rate of 3.54, HUM has a forward annual dividend rate of 3.54. Against a Trailing Annual Dividend Yield of 0.0137278475. The stock’s 5-year Average Dividend Yield is 0.83. The current Payout Ratio is 35.45% for HUM, which recently paid a dividend on 2025-06-27 with an ex-dividend date of 2025-09-26. Stock splits for the company last occurred on 1991-08-01 when the company split stock in a 3:2 ratio.
Earnings Estimates
The market rating for Humana Inc (HUM) is a result of the insights provided by 21.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$3.74, with high estimates of -$2.97 and low estimates of -$4.43.
Analysts are recommending an EPS of between $17.26 and $16.57 for the fiscal current year, implying an average EPS of $17.03. EPS for the following year is $13.64, with 25.0 analysts recommending between $15.85 and $10.42.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $31.99B. It ranges from a high estimate of $32.21B to a low estimate of $31.4B. As of the current estimate, Humana Inc’s year-ago sales were $29.4BFor the next quarter, 16 analysts are estimating revenue of $31.87B. There is a high estimate of $32.38B for the next quarter, whereas the lowest estimate is $31.07B.
A total of 19 analysts have provided revenue estimates for HUM’s current fiscal year. The highest revenue estimate was $129.03B, while the lowest revenue estimate was $126.97B, resulting in an average revenue estimate of $128.21B. In the same quarter a year ago, actual revenue was $117.76BBased on 19 analysts’ estimates, the company’s revenue will be $134.98B in the next fiscal year. The high estimate is $145.97B and the low estimate is $121.6B.
